Kubo N
Jpn J Antibiot. 1977 Nov;30(11):906-10.
Clinical study of sustained release cephalexin (S-6435 and S-6436) was conducted with the following results: 1) Pediatric patients with 1.5 approximately 12 years of age having acute tonsillitis and pharyngitis were orally administered 500 approximately 1,000 mg/day of S-6435 or S-6436 divided into 2 doses after breakfast and dinner. Out of 21 patients receiving the preparations, 19 patients satisfactorily responded to them and 2 fairly did. 2) In only one patient of the 21, rash was observed during the treatment. The side effect, however, disappeared 2 days after the initiation of the treatment, and was considered to be due to underlying disease of the patient. No other side effects were observed. Since it has become our concern to conduct injectable therapy in children, oral therapy should first be recommended to them. However, oral drugs, like a regular cephalexin, requiring q.i.d. regimen are inconvenient in giving the drugs to patients because they have to take the drugs once at midnight. S-6435 and S-6436, however, have no such disadvantages and prove to have as much effectiveness and safety as regular cephalexin has.
对头孢氨苄缓释制剂（S - 6435和S - 6436）进行了临床研究，结果如下：1）对年龄在1.5至12岁患有急性扁桃体炎和咽炎的儿科患者，早餐和晚餐后分2次口服给予500至1000毫克/天的S - 6435或S - 6436。在接受该制剂的21名患者中，19名患者反应良好，2名患者反应一般。2）在这21名患者中，仅1名患者在治疗期间出现皮疹。然而，该副作用在治疗开始后2天消失，被认为是由患者的基础疾病引起的。未观察到其他副作用。由于我们关注儿童的注射治疗，所以应首先向他们推荐口服治疗。然而，像常规头孢氨苄那样需要每日4次给药方案的口服药物，给患者服药带来不便，因为他们必须在午夜服药一次。然而，S - 6435和S - 6436没有这样的缺点，并且已证明具有与常规头孢氨苄相同的有效性和安全性。
